Siemens Fonds Invest GmbH Acquires New Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Siemens Fonds Invest GmbH acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 12,496 shares of the biotechnology company's stock, valued at approximately $821,000.

Several other hedge funds have also recently bought and sold shares of BMRN. Shell Asset Management Co. grew its position in BioMarin Pharmaceutical by 90.2% during the 4th quarter. Shell Asset Management Co. now owns 4,783 shares of the biotechnology company's stock worth $314,000 after acquiring an additional 2,268 shares during the last quarter. Sherbrooke Park Advisers LLC acquired a new position in BioMarin Pharmaceutical in the fourth quarter worth $362,000. Rafferty Asset Management LLC grew its holdings in shares of BioMarin Pharmaceutical by 2.0% during the fourth quarter. Rafferty Asset Management LLC now owns 207,839 shares of the biotechnology company's stock worth $13,661,000 after purchasing an additional 4,005 shares during the last quarter. Raiffeisen Bank International AG acquired a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at $1,025,000. Finally, Point72 Europe London LLP bought a new position in shares of BioMarin Pharmaceutical in the fourth quarter valued at about $3,993,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

BMRN has been the topic of a number of research analyst reports. Piper Sandler raised their price objective on shares of BioMarin Pharmaceutical from $122.00 to $126.00 and gave the company an "overweight" rating in a research report on Thursday, February 20th. Bank of America raised their price target on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the company a "buy" rating in a report on Thursday, February 20th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $90.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Wall Street Zen upgraded BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 25th. Finally, Oppenheimer upgraded BioMarin Pharmaceutical from a "market perform" rating to an "outperform" rating and set a $98.00 target price for the company in a research report on Monday, February 24th. Six research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, BioMarin Pharmaceutical currently has a consensus rating of "Moderate Buy" and an average target price of $93.45.

BioMarin Pharmaceutical Stock Down 1.1%

Shares of BMRN stock traded down $0.61 on Friday, hitting $57.40. 342,862 shares of the stock were exchanged, compared to its average volume of 1,865,815. The company has a current ratio of 5.33, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $11.01 billion, a P/E ratio of 26.07, a price-to-earnings-growth ratio of 0.61 and a beta of 0.27. BioMarin Pharmaceutical Inc. has a fifty-two week low of $52.93 and a fifty-two week high of $94.85. The business has a 50-day moving average of $62.70 and a 200 day moving average of $64.85.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, topping analysts' consensus estimates of $0.54 by $0.18. The firm had revenue of $747.31 million during the quarter, compared to the consensus estimate of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. Equities analysts anticipate that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

Insiders Place Their Bets

In other news, CAO Erin Burkhart sold 1,786 shares of the company's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $59.31, for a total transaction of $105,927.66. Following the completion of the sale, the chief accounting officer now directly owns 14,173 shares in the company, valued at approximately $840,600.63. This represents a 11.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 4,698 shares of company stock worth $308,172 in the last quarter. Corporate insiders own 0.85% of the company's stock.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.